Table 4.

PDX model in targeted therapy research

Reference	Drug name	Drug administration method	Gene target	Cancer type	Application scenario
Schueler et al.266	Gefitinib	Oral gavage	EGFR	NSCLC	Drug resistance mechanism study
Zhang et al.267	ASK120067	Oral gavage	EGFR	NSCLC	Novel drug validation
Chew et al.268	AZD4547, BLU9931	oral gavage	FGFR1, FGFR2, FGFR4	breast cancer	Therapeutic target identification
Krytska et al.269	crizotinib	Intraperitoneal Injections	ALK	Neuroblastoma	Drug combination validation
Shattuck-Brandt et al.270	KRT-232	oral gavage	MDM2	Metastatic Melanoma	Therapeutic target identification
Kinsey et al.271	trametinib	oral gavage	MEK	Pancreatic ductal adenocarcinoma	Drug combination validation
Coussy et al.272	BYL-719;	oral gavage	PI3K	PIK3CA-mutated metaplastic breast cancer	Drug combination validation
	selumetinib	oral gavage	MEK
Coussy et al.181	BAY80-6946;	N/A	PI3K p110α subunit	enzalutamide-resistant luminal androgen receptor triple-negative breast cancer	Therapeutic target identification
	PF-04691502;		mTOR and PI3K
	AZD2014		mTORC1 and mTORC2
Hsu et al.273	MLN0128	oral gavage	dual mTOR complex HER 2	HR + /HER2 + Breast Cancer	Drug combination validation
	trastuzumab	intraperitoneal injection
Harris et al.274	pertuzumab/trastuzumab	oral gavage	HER2	Ovarian cancer	Drug combination validation
Hashimoto et al.275	U3-1402	intravenous	HER3	HER3 positive cancer	Novel drug validation
Reddy et al.276	Pan-HER	Intraperitoneal injection	Pan-HER antibody mixture against EGFR, HER2, and HER3	TNBC	Drug combination validation
Odintsov et al.277	GSK2849330	intraperitoneal injection	HER3	NRG1-rearranged lung adenocarcinoma	Drug combination validation
Chen et al.278	compound 36 l	Intraperitoneal injection	KRAS‒PDEδ	pancreatic tumor	Novel drug preclinical validation
Barrette et al.279	Verteporfin	Intraperitoneal injection	YAP-TEAD	Glioblastoma	Novel drug preclinical validation
Hemming et al.280	YKL-5–124	Intraperitoneal injection	CDK7	Leiomyosarcoma	Therapeutic target identification
Gebreyohannes et al.193	Avapritinib	Oral gavage	Mutated KIT	Gastrointestinal Stromal Tumors	Novel drug preclinical validation
Karalis et al.281	Lenvatinib	Oral gavage	Multitargeted tyrosine kinase inhibitor	Gastric cancer	Novel drug preclinical validation
Dankner et al.282	Dabrafenib, encorafenib	Oral gavage	BRAF	Class II BRAF mutant melanoma	Drug combination validation
	Trametinib and binimetinib	Oral gavage	MEK
Knudsen et al.283	Palbociclib	Oral gavage	CDK4/6	Pancreatic cancer	Drug combination validation
	Trametinib	Oral gavage	MEK
Zhao et al.189	Neratinib	Oral gavage	Neratinib with CDK4/6, mTOR, and MEK inhibitors for the treatment of HER2 + cancer.	Pan-cancer	Drug combination validation
Yao et al.48	Cetuximab	Intraperitoneal injection	EGFR	Colorectal Cancer	Drug combination validation
	LSN3074753	Oral gavage	RAF
Gymnopoulos et al.284	TR1801-ADC	Intravenous injection	CMet	Pan-cancer	Novel drug preclinical validation
Vaisitti et al.285	VLS-101	Intravenous injection	ROR1	Richter syndrome	Novel drug preclinical validation
Haikala et al.233	HER3-DXd	Intravenous injection	HER3	EGFR mutant non-small cell lung cancer	Novel drug preclinical validation